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SUMMARY 
Main goal of this thesis is to investigate the use of non-invasive sources of information, 
specifically imaging and blood biomarkers, for disease management and overall survival 
assessment of non-small cell lung cancer (NSCLC) patients. This follows the premise of 
an individualized and personalized medicine, further explained in Chapter 2, in which 
data mining approaches and outcomes modelling, to tailor treatment and enhance 
outcomes in oncology, by means of a rapid learning health care approach in radiothera-
py are discussed.  
 To describe tumours’ heterogeneity in a non-invasive manner from medical imaging, 
derive from it prognostic information, and potentially capture its underlying genomic 
and proteomic profile resumes the main hypothesis behind Radiomics, presented in 
Chapter 3. This thesis, is focused particularly on the metabolic distribution of 18F-
fluorodeoxyglucose (FDG) uptake patterns, as measured by positron emission tomogra-
phy (PET) in NSCLC patients, treated radically with radiotherapy. Chapter 4 presents a 
study conducted for intensity volume histograms (IVH - similar in concept to the dose-
volume histograms (DVH), describing tumour’s FDG uptake distribution as a function of 
its volume, and vice-versa) derived from baseline scans (prior to radiotherapy). These 
features showed great potential for survival assessment on a large dataset of NSCLC 
patients (n=220). In Chapter 5, an integrated stability analysis of Radiomics features is 
discussed. In a test-retest setting, PET scans of 11 liver cancer patients were acquired 
one day apart, with no treatment administered in between. In an inter-observer cohort, 
manual segmentations of the primary tumour were made by five independent and 
experienced radiation oncologist, blinded to each other’s delineations (23 patients). 
Solely features achieving a high stability in both tests, measured by an intraclass corre-
lation (ICC) were retained for analysis presented in sequent chapters. In Chapter 6 the 
percentage variation of Radiomics features early during radiotherapy was analysed - 
“Delta Radiomics”. A multivariable model was developed (n=52), and validated in two 
independent datasets (n=32 and 26). Final model included, at least, one variable from 
each category, and reached an performance of a concordance-index of 0.66 (external = 
0.64 and 0.57). Finally, in Chapter 7 the hypothesis that metastatic lymph nodes provide 
extra prognostic value in addition to the primary tumour was investigated through 
Radiomics features derived from each structure. A prognostic model was fitted on data 
from 262 patients and validated on an external cohort (n=50). Model selection amongst 
features exclusively extracted from the metastatic lymph nodes achieved a statistically 
higher performance (0.62) than solely from primary tumour (0.53). 
 Chapter 8 summarizes the improvement of a validated clinical model (from 0.66 to 
0.70) by adding blood markers of hypoxia (Osteopontin) and tumour load (cytokeratin 
fragment 21-1) for 182 patients, and validated in 181 independent ones.  
